GlassScriptPhysician profile
Tamara Lynn Broadhead
NPI 1124548789
$2,052.76
in general payments reported to CMS, 2019-2025
17 companies · $293 in 2025
The $293 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $272 · 2022: $247 · 2023: $307 · 2024: $934 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,533.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $583.47 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $263.97 | 2021-2025 | Invega Sustenna, Spravato |
| Neurocrine Biosciences, INC. | $244.35 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $142.12 | 2023-2025 | Austedo Xr, Austedo Xr |
| Lundbeck LLC | $132.60 | 2022-2025 | Rexulti |
| Alkermes, INC. | $117.64 | 2024 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $107.79 | 2023-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $102.73 | 2021-2024 | Qelbree |
| Corium, LLC | $96.83 | 2022-2025 | Azstarys |
| Tris Pharma INC | $57.17 | 2022-2024 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $56.50 | 2021-2024 | Fanapt |
| Axsome Therapeutics, INC. | $41.13 | 2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $35.30 | 2022-2024 | Trintellix |
| Idorsia Pharmaceuticals US INC | $22.13 | 2022 | |
| Ironshore Pharmaceuticals INC. | $18.62 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $16.62 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Broadhead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.